Thyroid Hormone Deiodinases - A Selenoenzyme Family Acting as Gate Keepers to Thyroid Hormone Action

Acta Medica Austriaca

Volumn 23, Issue 1-2, 1996, Pages 17-30

  Kohrle J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Brain; Deiodination; Intracrine regulation; Kidney; Liver; Pituitary; Placenta; Receptor; Selenium; Thyroid hormone metabolism; Tissue distribution

Indexed keywords

IODIDE PEROXIDASE; ISOENZYME; PROTEIN; SELENIUM; SELENOPROTEIN; THYROID HORMONE;

ANIMAL; BRAIN; ENZYMOLOGY; HOMEOSTASIS; HUMAN; HYPOPHYSIS; KIDNEY; LIVER; METABOLISM; PHYSIOLOGY; PLACENTA; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; HOMEOSTASIS; HUMANS; IODIDE PEROXIDASE; ISOENZYMES; KIDNEY; LIVER; PITUITARY GLAND; PLACENTA; PROTEINS; SELENIUM; SELENOPROTEINS; THYROID HORMONES; TISSUE DISTRIBUTION;

EID: 0029696059     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (134)

1. Gross J, Pitt-Rivers R: The identification of 3, 5, 3′-triiodothyronine in human plasma. Lancet 1952;I:439-441.
2. Braverman LE, Ingbar SH, Sterling K: Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic subjects. J Clin Invest 1970;49:855-864.
3. Sterling K, Brenner MA, Newmann ES: Conversion of thyroxine to triiodothyronine in normal human subjects. Science 1970;169:1099-1100.
4. Sakurada T, Rudolph M, Fang SL, Vagenakis AG, Braverman LE, Ingbar SH: Evidence that triiodothyronine and reverse triodothyronine are sequentially deiodinated in man. J Clin Endocrinol Metab 1978;46:916-928.
5. Köhrle J, Leonard JL: Intracellular pathways of iodothyronine metabolism, in Braverman LE, Utiger RD (eds): Werner and Ingbar's The Thyroid - A Fundamental and Clinical Text. Philadelphia, Lippincott, 1996, in press.
6. Hesch RD, Brunner G, Soeling HD: Conversion of thyroxine (T4) and Triiodothyronine (T3) and the subcellular localisation of the converting enzyme. Clin Chim Acta 1975;59:209-213.
7. Visser TJ, van der Does-Tobe I, Docter R, Hennemann G: Conversion of thyroxine into tri-iodothyronine by rat liver homogenate. Biochem J 1975;150:489-493.
8. Köhrle J, Oertel M, Hoang-Vu C, Schnieders F, Brabant G: Type I 5′-deiodinase - a marker for differentiated thyroid carcinoma? Exp Clin Endocrinol 1993;101 (Suppl.3):60-72.
9. Berry MJ, Banu L, Larsen PR: Type I iodothyronine deiodinase is a selenocystein-containing enzyme. Nature 1991;349:438-440.
10. Davey JC, Becker KB, Schneider MJ, St.Germain DL, Galton VA: Cloning of a cDNA for the type II iodothyronine deiodinase. J Biol Chem 1995;270:26786-26789.
11. Croteau W, Whittemore SK, Schneider MJ, St.Germain DL: Cloning and expression of a cDNA for a mammalian type III iodothyronine deiodinase. J Biol Chem 1995;270:16569-16575.
12. Salvatore D, Low SC, Berry M, Maia AL, Harney JW, Croteau W, St.Germain DL, Larsen PR: Type 3 iodothyronine deiodinase: cloning, in vitro expression, and functional analysis of the placental selenoenzyme. J Clin Invest 1995;96:2421-2430.
13. Maia AL, Berry MJ, Sabbag R, Harney JW, Larsen PR: Structural and functional differences in the dio 1 gene in mice with inherited type 1 deiodinase deficiency. Mol Endocrinol 1995;9:969-980.
14. Jakobs T, Schmutzler C, Köhrle J: Identification of a T3 responsive element in the upstream regulatory region of the human type I 5′-deiodinase gene. Thyroid 1995;5:S130(A).
15. Jakobs T, Schmutzler C, Meissner J, Köhrle J: Functional characterization of a thyroid hormone response element in the promoter of human type I iodothyronine-5′-deiodinase. Exp Clin Endocrinol Diabetes 1996;104:16(A).
16. Yen PM, Chin WW: New advances in understanding the molecular mechanisms of thyroid hormone action. Trends in Endocrinology and Metabolism 1994;5:65-72.
17. Oppenheimer JH, Schwartz HL, Mariash CN, Kinlaw WB, Wong NCW, Freake HC: Advances in our understanding of thyroid hormone action at the cellular level. Endocr Rev 1987;8:288-308.
18. Brent GA: The molecular basis of thyroid hormone action. N Engl J Med 1994;331:847-853.
19. Farwell AP, Tranter MP, Leonard JL: Thyroxine-dependent regulation of integrin-laminin interactions in astrocytes. Endocrinology 1995;136:3909-3915.
20. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839.
21. Leonard JL, Visser TJ: Biochemistry of deiodination, in Hennemann G (ed): Thyroid hormone metabolism. New York, Marcel Dekker Inc., 1986, pp189-229.
22. Leonard JL, Rosenberg IN: Iodothyronine 5′-deiodinase from rat kidney: Substrate specificity and the 5′-deiodination of reverse triiodothyronine. Endocrinology 1980;107:1376-1383.
23. Leonard JL, Ekenbarger DM, Frank SJ, Farwell AP, Köhrle J: Localization of type I iodothyronine 5′deiodinase to the basolateral plasma membrane of rat kidney and LLC-PK1 renal cortical cells. J Biol Chem 1991;266:11262-11269.
24. Lee WS, Berry MJ, Hediger MA, Larsen PR: The type I iodothyronine 5′-deiodinase messenger ribonucleic acid is localized to the S3 segment of the rat kidney proximal tubule. Endocrinology 1993;132:2136-2140.
25. Köhrle J: Thyrotropin (TSH) action on thyroid hormone deiodination and secretion: One aspect of thyrotropin regulation of thyroid cell biology. Horm Metab Res 1990;23 Suppl:18-28.
26. Menjo M, Murata Y, Fujii T, Nimura Y, Seo H: Effects of thyroid and glucocorticoid hormones on the level of messenger ribonucleic acid for iodothyronine type I 5′-deiodinase in rat primary hepatocyte cultures grown as spheroids. Endocrinology 1993;133:2984-2990.
27. Maia AL, Harney JW, Larsen PR: Pituitary cells respond to thyroid hormone by discrete, gene-specific pathways. Endocrinology 1995;136:1488-1494.
28. Maia AL, Kieffer JD, Harney JW, Larsen PR: Effect of 3, 5, 3′-triiodothyronine (T3) administration on diol gene expression and T3 metabolism in normal and type I deiodinase-deficient mice. Endocrinology 1995;136:4842-4849.
29. Baur A, Köhrle J: Pituitary type I 5′-deiodinase is rapidly stimulated by T3 and 3, 5, -T2 and is involved in T3-degradation by tyrosyl ring 5-deiodination. 4th Int Pituitary Congress, San Diego, 1996(A).
30. Kaminski T, Köhrle J, Ködding R, Hesch RD: Autoregulation of 3, 3′, 5′-triiodothyronine production by rat liver microsomes. Acta Endocrinol 1981;98:240-245.
31. Moreno M, Berry MJ, Horst C, Thoma R, Goglia F, Harney JW, Larsen PR, Visser TJ: Activation and inactivation of thyroid hormone by type I iodothyronine deiodinase. FEBS Lett 1994;344:143-146.
32. Larsen PR, Silva JE, Kaplan MM: Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr Rev 1981;2:87-102.
33. Visser TJ, Kaptein E, Terpstra OT, Krenning EP: Deiodination of thyroid hormone by human liver. J CHn Endocrinol Metab 1988;67:17-24.
34. St.Germain DL, Croteau W: Ligand-induced inactivation of type I iodothyronine 5′-deiodinase: Protection by propylthiouracil in vivo and reversibility in vitro. Endocrinology 1989;125:2735-2744.
35. Köhrle J, Rasmussen UB, Ekenbarger DM, Alex S, Rokos H, Hesch RD, Leonard JL: Affinity labeling of rat liver and kidney type I 5′-deiodinase. Identification of the 27-kDa substrate binding subunit. J Biol Chem 1990;265:6155-6163.
36. Auf dem Brinke D, Hesch RD, Köhrle J: Re-examination of the subcellular localization of thyroxine-5′-deiodination in rat liver. Biochem J 1979;180:273-279.
37. Fekkes D, van Overmeeren-Kaptein E, Docter R, Hennemann G, Visser TJ: Location of rat liver iodothyronine deiodinating enzymes in the endoplasmic reticulum. Biochim Biophys Acta 1979;587:12-19.
38. Santini F, Chiovato L, Lapi P, Lupetti M, Dolfi A, Bianchi F, Bernardini N, Bendinelli G, Mammoli C, Vitti P, Chopra IJ, Pinchera A: The location and the regulation of the type I-iodothyronine 5′-monodeiodinase (type I-MD) in the rat thyroid: studies using a specific anti-type I-MD antibody. Mol Cell Endocrinol 1995;110:195-203.
39. Toyoda N, Berry MJ, Harney JW, Larsen PR: Topological analysis of the integral membrane protein, type 1 iodothyronine deiodinase (D1). J Biol Chem 1995;270:12310-12318.
40. Mol JA, Docter R, Kaptein E, Jansen G, Hennemann G, Visser TJ: Inactivation and affinity labeling of rat liver iodothyronine deiodinase with N-bromoacetyl-3, 3′, 5-triiodothyronine. Biochem Biophys Res Comm 1984;124:475-483.
41. Köhrle J, Rasmussen UB, Rokos H, Leonard JL, Hesch RD: Selective affinity labeling of a 27-kDa integral membrane protein in rat liver and kidney with N-bromoacetyl derivatives of L-thyroxine and 3, 5, 3′-triiodo-L-thyronine. J Biol Chem 1990;265:6146-6154.
42. Behne D, Kyriakopoulos A, Meinhold H, Köhrle J: Identification of type I iodothyronine 5′-deiodinase as a selenoenzyme. Biochem Biophys Res Commun 1990;173:1143-1149.
43. Berry MJ, Kieffer JD, Larsen PR: Evidence that cysteine, not selenocysteine, is in the catalytic site of type II iodothyronine deiodinase. Endocrinology 1991;129:550-552.
44. Berry MJ, Kieffer JD, Harney JW, Larsen PR: Selenocysteine confers the biochemical properties characteristic of the type I iodothyronine deiodinase. J Biol Chem 1991;266:14155-14158.
45. Berry MJ: Identification of essential histidine residues in rat Type I iodothyronine deiodinase. J Biol Chem 1992;267:18055-18059.
46. Toyoda N, Harney JW, Berry MJ, Larsen PR: Identification of critical amino acids for 3, 5, 3′-triiodothyronine deiodination by human type 1 deiodinase based on comparative functional-structural analyses of the human, dog, and rat enzymes. J Biol Chem 1994;269(32):20329-20334.
47. Nagayama Y, Harakawa S, Taguchi A, Takeshita A, Eguchi K, Yokoyama N, Nagataki S: In vivo effect of gold compounds on thyroxine to triiodothyronine conversion by type I 5′-deiodinase in patients with rheumatoid arthritis. Horm Metab Res 1993;25:657-658.
48. Mandel SJ, Brent GA;, M.; Larsen: Prospective studies of thyroid functions in patients receiving gold therapy. Thyroid 1995;5:113-116.
49. Leonard JL, Visser TJ: Selective modification of the active center of renal iodothyronine 5′-deiodinase by iodoacetate. Biochim Biophys Acta 1984;787:122-130.
50. Köhrle J: Pharmacokinetics and metabolism of thyroid hormones, in Orgiazzi J, Leclère J (eds): The Thyroid and Tissues. Stuttgart, Schattauer, 1994, pp3-32.
51. Cavalieri RR, Pitt-Rivers R: The effects of drugs on the distribution and metabolism of thyroid homrones. Pharmacol Rev 1981;33:55-80.
52. Köhrle J: Von Pflanzenextrakten zu Hormonantagonisten - Neue experimentelle Konzepte zur Hyperthyreosetherapie, in Reinwein D, Weinheimer B (eds): Schilddrüse 1993. Berlin, De Gruyter, 1994, pp210-233.
53. Schröder-van der Elst J, Van der Heide D, Köhrle J: in vivo effects of flavonoid EMD 21388 on thyroid hormone secretion and metabolism in the rat. Am J Physiol 1991;261:E227-E232.
54. Weintraub BD. Molecular Endocrinology - basic concepts and clinical correlations. New York, Raven Press, 1995.
55. Refetoff S, Weiss RE, Usala SJ: The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14:348-399.
56. McPhaul MJ, Marcelli M, Zoppi S, Griffin JE, Wilson JD: Genetic basis of endocrine disease 4 - the spectrum of mutations in the androgen resistance. J Clin Endocrinol Metab 1993;76(1):17-23.
57. Brönnegard M, Carlstedt-Duke J: The genetic base of glucocorticoid resistance. TEM 1995;6:160-164.
58. Smith EP, Boyd J, Takahashi GR: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061.
59. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G: Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene (see comments). N Engl J Med 1995;332:150-154.
60. Ledent C, Parma J, Dumont JE, Vassart G, Targovnik H: Molecular genetics of thyroid diseases. Eur J Endocrinol 1994;130:8-14.
61. Bikker H, den Hartog MT, Baas F, Gons MH, Vulsma T, De Vijlder JJ: A 20-basepair duplication in the human thyroid peroxidase gene results in a total iodide organification defect and congenital hypothyroidism. J Clin Endocrinol Metab 1994;79:248-252.
62. Ledent C, Parmentier M, Vassart G, Dumont JE: Models of thyroid goiter and tumors intransgenic mice. Mol Cell Endocrinol 1994;100:167-169.
63. Curtis AJ, Scrimshaw BJ, Topliss DJ, Stockigt JR, George PM, Barlow JW: Thyroxine binding by human transthyretin variants: mutations at position 119, but not position 54, increase thyroxine binding affinity. J Clin Endocrinol Metab 1994;78:459-462.
64. Langsteger W, Stockigt JR, Docter R, Költringer P, Lorenz O, Eber O: Familial dysalbuminaemic hyperthyroxinaemia and inherited partial TBG deficiency: first report. Clin Endocrinol 1994;40:751-758.
65. Takeda K, Iyota K, Mon Y, Tamura Y, Suehiro T, Kubo Y, Refetoff S, Hashimoto K: Gene screening in Japanese families with complete deficiency of thyroxine-binding globulin demonstrates that a nucleotide deletion at codon 352 may be a race specific mutation. Clin Endocrinol 1994;40:221-226.
66. Watson AY, Leonard JL, Radie KA, Meilen SA, Murphy RA: Alterations in the pituitary-thyroid axis and 5′-deiodinase activity in mice with muscular dystrophy. Endocrinology 1985;116:2201-2208.
67. Schoenmakers CH, Pigmans IG, Poland A, Visser TJ: Impairment of the selenoenzyme type I iodothyronine deiodinase in C3H/He mice. Endocrinology 1993;132:357-361.
68. Berry MJ, Grieco D, Maia BA: Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5′ deiodinase deficiency. J Clin Invest 1993;92:1517-1528.
69. Young RA, Fang SL, Prosky J, Braverman LE: Hepatic conversion of thyroxine to triiodothyronine in obese and lean Zucker rats. Life Sci 1984;34:1783-1789.
70. Katzeff HL, Selgrad C: Impaired peripheral thyroid hormone metabolism in genetic obesity. Endocrinology 1993;132:989-995.
71. Hillgartner FB, Romsos DR: Impaired transport of thyroid hormones into livers of obese (ob/ob) mice. Am J Physiol 1988;255:E54-E58.
72. Hillgartner FB, Romsos DR: Regulation of iodothyronine 5′-deiodination in lean and obese (ob/ob) mice. Amer J Physiol Endocrinol Metab 1985;249:E209-E218.
73. Kleinhaus N, Faber J, Kahana L, Schneer J, Scheinfeld M: Euthyroid Hyperthyroxinemia Due to a generalized 5′-Deiodinase Defect. J Clin Endocrinol Metab 1988;66:684-688.
74. Maxon HR, Burman KD, Premachandra BN, Chen I-W, Burger A, Levy P, Georges LP: Familial elevations of total and free thyroxine in healthy, euthyroid subjects without detectable binding protein abnormalities. Acta Endocrinol 1982;100:224-230.
75. Köhrle J: Schilddrüsenhormonstoffwechsel 1983 - Untersuchungen zur enzymatischen Dejodierung von L-Thyroxin und anderen Jodthyroninen durch Lebergewebe der Ratte. Stuttgart, Ferdinand Enke Verlag, 1983, pp1-237.
76. Marie V, Dupuy F, Bazin R: Development of thyroxine type II deiodinase activity in brains of Zucker rats. Biochem J 1994;304:259-261.
77. Visser TJ, Kaplan MM, Leonard JL, Larsen PR: Evidence for two pathways of iodothyronine 5′deiodination in rat pituitary that differ in kinetics, propylthiouracil sensitivity, and response to hypothyroidism. J Clin Invest 1983;71:992-1002.
78. Murakami M, Tanaka K, Greer MA: There is a nyctohemeral rhythm of type II iodothyronine 5′-deiodinase activity in rat anterior pituitary. Endocrinology 1988;123:1631-1635.
79. Murakami M, Greer MA, Hjulstad S, Greer SE, Tanaka K: Evidence that rat pineal thyroxine 5′-deiodinase is primarily stimulated by - and not à-adrenergic agonists and that its adrenergic-stimulated and spontaneous rhythmic nocturnal rise require RNA and protein synthesis. Proc Soc Exp Biol Med 1989;190:190-194.
80. Guerrero JM, Gonzalez-Brito A, Santana C, Reiter RJ: Nocturnal increase of type II thyroxine 5′-deiodinase activity in the Syrian hamster harderian gland is abolished by light exposure and induced by isoproterenol (42848). Proc Soc Exp Biol Med 1989;190:186-189.
81. Bernai J, Nunez J: Thyroid hormones and brain development. Eur J Endocrinol 1995;133:390-398.
82. Silva JE: Thyroid hormone control of thermogenesis and energy balance. Thyroid 1995;5:481-492.
83. Houstek J, Vizek K, Pavelka S, Kopecky J, Krejcova E, Hermanska J, Cermakova M: Type II iodothyronine 5′-deiodinase and uncoupling protein in brown adipose tissue of human newborns. J Clin Endocrinol Metab 1993;77:382-387.
84. Meinhold H, Campos-Barros A, Walzog B, Köhler R, Müller F, Behne D: Effects of selenium and iodine deficiency on Type I, Type II, and Type III iodothyronine deiodinases and circulating hormone levels in the rat. Exp Clin Endocrinol 1993;100:87-93.
85. Safran M, Farwell AP, Leonard JL: Evidence that type II 5′-deiodinase is not a selenoprotein. J Biol Chem 1991;266:13477-13480.
86. Köhrle J, Schomburg L, Drescher S, Fekete E, Bauer K: Rapid stimulation of type I 5′-deiodinase in rat pituitaries by 3, 3′, 5-triiodo-L-thyronine. Mol Cell Endocrinol 1995;108:17-21.
87. Baur A, Köhrle J: Iodothyronines regulate type I 5′-deiodinase in rat and human somatomammotroph pituitary cell lines. Exp Clin Endocrinol Diab 1996;104:24(A).
88. St.Germain DL, Schwartzman RA, Croteau W, Kanamori A, Wang Z, Brown DD, Galton VA: A thyroid hormone-regulated gene in Xenopus laevis encodes a type III iodothyronine 5-deiodinase. Proc Natl Acad Sci USA 1994;91:7767-7771.
89. St Germain DL, Schwartzman RA, Croteau W, Kanamori A, Wang Z, Brown DD, Galton VA: A thyroid hormone-regulated gene in Xenopus laevis encodes a type III iodothyronine 5-deiodinase. Proc Natl Acad Sci U S A 1994;91:11282.
90. Ringquist S, Schneider D, Gibson T, Baron C, Boeck A, Gold L: Recognition of the mRNA selenocysteine insertion sequence by the specialized translational elongation factor SELB. Genes Develop 1994;8:376-385.
91. Shen Q, Leonard JL, Newburger PE: Structure and function of the selenium translation element in the 3′-untranslated region of human cellular glutathione peroxidase mRNA. RNA 1995;1:519-525.
92. Sturchler-Pierrat C, Hubert N, Totsuka T, Mizutani T, Carbon P, Krol A: Selenocysteylation in eukaryotes necessitates the uniquely long aminoacyl acceptor stem of selenocysteine tRNAsec. J Biol Chem 1995;270:18570-18574.
93. Low SC, Harney JW, Berry MJ: Cloning and functional characterization of human selenophosphate synthetase, an essential component of selenoprotein synthesis. J Biol Chem 1995;270:21659-21664.
94. Behne D, Hilmert H, Scheid S, Gessner H, Elger W: Evidence for specific selenium target tissues and new biologically important selenoproteins. Biochim Biophys Acta 1988;966:12-21.
95. Burk RF, Hill KE: Regulation of Selenoproteins. Ann Rev Nutr 1993;13:65-81.
96. Chanoine JP, Braverman LE, Farwell AP, Safran M, Alex S, Dubord S, Leonard JL: The thyroid gland is a major source of circulating T3 in the rat. J Clin Invest 1993;91:2709-2713.
97. Bermano G, Nicol F, Dyer JA, Sunde RA, Beckett GJ, Arthur JR, Hesketh JE: Tissue-specific regulation of selenoenzyme gene expression during selenium deficiency in rats. Biochem J 1995;311:425-430.
98. Christensen MJ, Cammack PM, Wray CO: Tissue specificity of selenoprotein gene expression in rats. J Nutr Biochem 1995;6:367-372.
99. Gross M, Oertel M, Köhrle J: Differential selenium-dependent expression of type I 5′-deiodinase and glutathione peroxidase in the porcine epithelial kidney cell line LLC-PK1. Biochem J 1995;306:851-856.
100. Berry MJ, Banu L, Harney JW, Larsen PR: Functional characterization of the eukaryotic SECIS elements which direct selenocysteine insertion at UGA codons. EMBO J 1993;12:3315-3322.
101. Dumont JE, Corvilain B, Contempre B: The biochemistry of endemic cretinism: roles of iodine and selenium deficiency and goitrogens. Mol Cell Endocrinol 1994;100:163-166.
102. Köhrle J: Iod: Selen-und Iodversorgung - Endokrinologische Zusammenhänge, in Kruse-Jarres JD (ed): Mineralstoffe, Spurenelemente, Vitamine: Risikofaktoren - Messverfahren -Präventivmaßnahmen. Stuttgart, Biosynposia, 1996, pp61-105.
103. Yeh JY, Beilstein MA, Andrews JS, Whanger PD: Tissue distribution and influence of selenium status on levels of selenoprotein W. FASEB J 1995;9:392-396.
104. Karimpour I, Cutler M, Shih D, Smith J, Kleene KC: Sequence of the gene encoding the mitochondrial capsule selenoprotein of mouse sperm: identification of three in-phase TGA selenocysteine codons. DNA Cell Biol 1992;11:693-699.
105. Berger MM, Cavadini C, Chiolero R, Dirren H: Copper, selenium, and zinc status and balances after major trauma. J Traum Inj Infect Crit Care 1996;40:103-109.
106. Yang G, Zhou R: Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. J Trace Elem Electrolytes Health Dis 1994;8:159-165.
107. Köhrle J: Transfer und Stoffwechsel von Schilddrüsenhormonen in der Plazenta, in Usadel H, Weinheimer B (eds): Schilddrüse 1995. Berlin, Walter de Gruyter, 1996, in press.
108. Ekins RP, Sinha AK, Pickard MR, Evans IM, Al Yatama F: Transport of thyroid hormones to target tissues. Acta Med Austriaca 1994;21(2):26-34.
109. Chopra IJ: Nature, sources, and relative biological significance of circulating thyroid hormones, in Braverman LE, Utiger RD (eds): Werner and Ingbar's The Thyroid. Philadelphia, Lippincott, 1991, pp126-143.
110. Kaplan MM, Pan C, Gordon PR, Lee JK, Gilchrest BA: Human epidermal keratinocytes in culture convert thyroxine to 3, 5, 3′-triiodothyronine by type II iodothyronine deiodination. A novel endocrine function of the skin. J Clin Endocrinol Metab 1988;66:815-822.
111. Campos Barms A, Meinhold H, Kohler R, Muller F, Fravci M, Baumgartner A: The effects of desipramine on thyroid hormone concentrations in rat brain. Naunyn Schmiedebergs Arch Pharmacol 1995;351:469-474.
112. Baumgartner A, Campos-Barros A, Gaio U, Hessenius C, Flechner A, Meinhold H: Carbamazepine affects triiodothyronine production and metabolization in rat hippocampus. Life Sciences 1994;54:PL401-407.
113. Campos-Barros A, Hoell T, Musa A, Sampaolo S, Stoltenburg G, Pinna G, Eravci M, Meinhold H, Baumgartner A: Phenolic and tyrosyl ring deiodination and thyroid hormone concentrations in the human central nervous system. J Clin Endocrinol Metab 1996;in press:
114. Baumgartner A: Schilddrüsenhormone und depressive Erkrankungen - Kritische Übersicht und Perspektiven Teil 1: Klinik. Nervenarzt 1993;64:1-10.
115. Baumgartner A: Schilddrüsenhormone und depressive Erkrankungen - Kritische Übersicht und Perspektiven Teil 2: Nervenarzt 1993;64:11-20.
116. Whybrow PC: The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorder. Acta Med Austriaca 1994;21:47-52.
117. Borek C: Molecular mechanisms in cancer induction and prevention. Environ Health Perspect 1993;101 Suppl 3:237-245.
118. Schreck R, Schnieders F, Schmutzler C, Köhrle J: Retinoids stimulate Type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-798.
119. Schmutzler C, Hoang-Vu C, Schreck R, Bienert K, Köhrle J: Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Cancer Res 1996, submitted.
120. Brabant G, Maenhaut C, Köhrle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, Von zur Mühlen A, Vassart G, Dumont JE: Human thyrotropin receptor gene: Expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991;82:R7-R12.
121. Naumann A, Naumann J, Witeska A, Dutkiewiez M: 5′-Deiodinase Type I in human kidney cancer. J Endocrinol Invest 1993;16(Suppl.2):76(A).
122. Dutkiewicz S, Witeska A, Nauman A: The deiodination of thyroxine to triiodothyronine in the testes of patients with prostate cancer. Int Urol Nephrol 1995;27:81-85.
123. Köhrle J, Jakob F, Jany B, Wilms K: Cell differentiation and local regulatory systems. Internist 1995;36:378-384.
124. Dai G, Levy O, Carrasco N: Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-460.
125. Hesch RD. The 'Low T3-Syndrome'. London, Academic Press, 1981.
126. Wartofsky L, Burman KD: Alterations in thyroid function in patients with systemic illness: The 'euthyroid sick syndrome'. Endocr Rev 1993;3:164-217.
127. Boelen A, Platvoet-ter Schiphorst MC, Wiersinga WM: Soluble cytokine receptors and the low 3, 5, 3′-triiodothyronine syndrome in patients with nonthyroidal disease. J Clin Endocrinol Metah 1995;80:971-976.
128. Toyoda N, Zavacki AM, Maia AL, Harney JW, Larsen PR: A novel retinoid X receptor-indepent thyroid hormone response element is present in the human type I deiodinase gene. Mol Cell Biol 1995;15:5100-5112.
129. Berger MM, Lemarchand Béraud T, Cavadini C, Chioléro R: Immediate decrease of serum selenium after major trauma without significant losses: cue to the 'Low T3 Syndrome'? Clin Intensive Care 1994;5:76(A).
130. Zimmermann T, Albrecht S, Nagel M, Bauer R, Menschikowski M, Saeger HD: Low T3 syndrome in septic patients - Phenomenon or important pathogenetic factor. Exp Clin Endocrinol Diabetes 1996;104:91(A).
131. Lim CF, Stockigt JR G: Alterations in hepatocyte uptake and plasma binding of thyroxine in nonthyroidal illness and caloric deprivation. TEM 1995;6:17-20.
132. Vos RA, De Jong M, Bernard BF, Docter R, Krenning EP, Hennemann G: Impaired thyroxine and 3, 5, 3′-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. J Clin Endocrinol Metah 1995;80:2364-2370.
133. Hesch RD, Hüsch M, Ködding R, Höffken B, Meyer T: Treatment of dopamine-dependent shock with triiodothyronine. Endocr Res Commun 1981;8:229-237.
134. Burman KD, Wartofsky L, Dinterman RE, Kesler P, Wannemacher RW: The effect of T3 and reverse T3 administration on muscle protein catabolism during fasting as measured by 3-methylhistidine excretion. Metabolism 1979;28:805-813.